PanTera

Executive Summary

PanTera is a Belgian radiopharmaceutical company dedicated to enabling the widespread adoption of targeted alpha therapy for cancer by ensuring a reliable, large-scale supply of actinium-225 (Ac-225). Ac-225 is a highly promising alpha-emitting radioisotope that offers potent, localized cancer cell killing with minimal off-target effects, yet its clinical use has been limited by scarce and inconsistent production. PanTera aims to solve this bottleneck by building a dedicated manufacturing facility in Mol, Belgium, to produce Ac-225 as an Active Product Ingredient (API) for the global pharmaceutical market. Since its founding in 2015, the company has focused on process development and scale-up, positioning itself as a key enabler for the emerging targeted radiotherapies sector. The company's strategy centers on establishing a robust, cGMP-compliant production platform capable of meeting anticipated demand from radiopharmaceutical developers worldwide. PanTera's facility in Mol is designed to produce multi-curie quantities of Ac-225 using a proprietary process, with the goal of supplying clinical and commercial-stage partners. By securing a stable, high-purity supply of Ac-225, PanTera aims to accelerate the development and commercialization of novel targeted alpha therapies (TATs) for various cancers. The company's value proposition is critical as the radiopharmaceutical field moves toward personalized medicine, where alpha emitters like Ac-225 offer unique therapeutic advantages. With growing interest from pharma and biotech, PanTera is well-positioned to become a leading supplier in this niche but rapidly expanding market.

Upcoming Catalysts (preview)

• Q4 2026Completion of Ac-225 Production Facility in Mol80% success
• H1 2027First Commercial Supply Agreement with a Pharmaceutical Partner70% success
• Q2 2026Series B Funding Round for Scale-Up75% success